feed,title,long_url,short_url
Benzinga,"Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients",https://benzinga.com/general/biotech/21/05/21272358/exelixis-cabometyx-roches-tecentriq-combo-achieves-27-orr-in-high-risk-prostate-cancer-patients,https://j.mp/2Sof4fJ
